Gonorrhea: Treatment and management considerations for the male patient

Brian Dalke, Timothy Ivers, Karen K. O’Brien, Shana Castillo, Eric Hoie, Kimberley J. Begley

Research output: Contribution to specialist publicationArticle

1 Scopus citations

Abstract

Gonorrhea is the second most common communicable disease in the United States. From 2010 to 2014, the rate of this sexually transmitted disease increased by 10.5% in the U.S. Cefixime, which was once the first-line agent for the treatment of Neisseria gonorrhoeae, is rapidly waning in efficacy, as are several other cephalosporins. Similarly, fluoroquinolone-resistant strains of N gonorrhoeae have been reported. As a result, the use of these agents has decreased. The CDC currently recommends dual treatment with ceftriaxone and azithromycin for most gonococcal infections. Multidrug-resistant gonorrhea is becoming a serious health threat in the U.S.

Original languageEnglish (US)
Pages41-44
Number of pages4
Volume41
No8
Specialist publicationU.S. Pharmacist
StatePublished - Aug 1 2016

All Science Journal Classification (ASJC) codes

  • Pharmacy
  • Pharmacology
  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Gonorrhea: Treatment and management considerations for the male patient'. Together they form a unique fingerprint.

Cite this